Cancer cells surviving cisplatin chemotherapy increase stress-induced OMA1 activity and mitochondrial fragmentation
Abstract
Abstract Cancer is one of the leading causes of deaths worldwide. Once cancer cells acquire therapy resistance, they become the main driver of cancer lethality in patients. Thus, mechanisms of therapy resistance must be investigated to improve patient outcomes. Mitochondria are critical organelles in the cellular stress responses, undergoing dynamic morphological and functional changes in response to external stimuli. We and others have identified a chemotherapy-resistant cancer cell state where cells that survive treatment exhibit a dramatic increase in cell size and remain non-proliferative for weeks. In this study, we demonstrate that cancer cells that enter this resistant cell state in response to cisplatin increase OMA1 activity and decrease mitochondrial fusion and function to combat oxidative stress. These findings contribute to further understanding the role of the mitochondrial stress responses in therapy resistance in cancer and provide a potential therapeutic avenue to targeting cancer cells that enter this chemotherapy-resistant cell state.
Article Details
Authors (8)
Melvin Li
Chenille A. McCullum
Louis T. A. Rolle
Qin Ni
Institute for NanoBioTechnology
Zhuoxu Ge
Institute for NanoBioTechnology
Sean X. Sun
Institute for NanoBioTechnology
Kenneth J. Pienta
Urology, Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering Cancer Ecology Center at the Brady Urological Institute Johns Hopkins University Baltimore Maryland USA
Sarah R. Amend
Urology and Oncology Cancer Ecology Center at the Brady Urological Institute Johns Hopkins School of Medicine Baltimore Maryland USA